General Information of Drug (ID: DMGIR3F)

Drug Name
P5091 Drug Info
Synonyms
882257-11-6; P005091; 1-(5-(2,3-dichlorophenylthio)-4-nitrothiophen-2-yl)ethanone; P-5091; 1-[5-(2,3-Dichloro-phenylsulfanyl)-4-nitro-thiophen-2-yl]-ethanone; CHEMBL2159495; P5091 (P005091); 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitrothiophen-2-yl]ethanone; 1-(5-((2,3-Dichlorophenyl)thio)-4-nitrothiophen-2-yl)ethanone; Cyto5D7; C12H7Cl2NO3S2; SCHEMBL2681288; DTXSID90384841; 1-[5-[(2,3-Dichlorophenyl)thio]-4-nitro-2-thienyl]ethanone; HMS3653E09; HMS3743M19; ZINC125366; BCP07750; EX-A2120; BDBM50393437; MFCD00123202; s7132; AKOS024458314; CCG-240421; CS-1445; MCULE-6661883192; QC-8200; SB19505; AC-32692; AK270202; BS-17872; DA-40897; HY-15667; FT-0714931; SW219710-1; Y1893; J3.502.625H; P 5091; P-05091; P005091(P5091); P 005091; P-005091; 1-[5-(2,3-dichlorophenyl)sulfanyl-4-nitro-2-thienyl]ethanone; 1-[5-(2,3-dichlorophenylsulfanyl)-4-nitro-2-thienyl]ethanone; 1-[5-[(2,3-Dichlorophenyl)thio]-4-n?itro-2-thienyl]ethanone; 1-{5-[(2,3-Dichlorophenyl)sulfanyl]-4-nitrothiophen-2-yl}ethan-1-one
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Preclinical [1]
Cross-matching ID
PubChem CID
2819993
CAS Number
CAS 882257-11-6
TTD Drug ID
DMGIR3F

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Patented Agent(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PMID26077642-Compound-Vif2 DMYXIS7 N. A. N. A. Patented [3]
PMID26077642-Compound-Vif1 DMS9KCF N. A. N. A. Patented [3]
ADC-03 DM21I35 Solid tumour/cancer 2A00-2F9Z Preclinical [4]
P22077 DMD8JIC Inflammation 1A00-CA43.1 Preclinical [5]
HBX19818 DM6GSI1 Solid tumour/cancer 2A00-2F9Z Preclinical [6]
ADC-01 DM19R28 Solid tumour/cancer 2A00-2F9Z Preclinical [4]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Herpesvirus ubiquitin-specific protease (HAUSP) TTXU3EQ UBP7_HUMAN Inhibitor [2]

References

1 Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018 Jan;17(1):57-78.
2 USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth. Biochem Pharmacol. 2017 May 1;131:29-39.
3 Deubiquitinases (DUBs) and DUB inhibitors: a patent review.Expert Opin Ther Pat. 2015;25(10):1191-1208.
4 Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics. Cancers (Basel). 2020 Jun 15;12(6):1579.
5 P22077 inhibits LPS-induced inflammatory response by promoting K48-linked ubiquitination and degradation of TRAF6. Aging (Albany NY). 2020 Jun 9;12(11):10969-10982.
6 Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther. 2009 Aug;8(8):2286-95.